Natarajan Sethuraman Sells 2,700 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 2,700 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $20.04, for a total transaction of $54,108.00. Following the sale, the insider now directly owns 160,888 shares of the company’s stock, valued at approximately $3,224,195.52. The trade was a 1.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Natarajan Sethuraman also recently made the following trade(s):

• On Monday, November 11th, Natarajan Sethuraman sold 1,409 shares of Entrada Therapeutics stock. The shares were sold at an average price of $20.01, for a total value of $28,194.09.
• On Wednesday, October 16th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.00, for a total value of $10,800.00.
• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.09, for a total transaction of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.24, for a total value of $9,144.00.

Entrada Therapeutics Stock Performance

NASDAQ TRDA opened at $19.04 on Friday. Entrada Therapeutics, Inc. has a 52-week low of $10.75 and a 52-week high of $20.49. The company has a fifty day moving average of $16.62 and a 200-day moving average of $15.85. The company has a market capitalization of $712.48 million, a P/E ratio of 11.97 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. The business had revenue of $94.69 million for the quarter, compared to analysts’ expectations of $55.00 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. As a group, analysts forecast that Entrada Therapeutics, Inc. will post 1.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors have recently made changes to their positions in TRDA. Vanguard Group Inc. lifted its stake in shares of Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after acquiring an additional 13,742 shares during the last quarter. American Century Companies Inc. increased its stake in Entrada Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock worth $5,486,000 after purchasing an additional 18,625 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Entrada Therapeutics by 14.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 185,984 shares of the company’s stock valued at $2,972,000 after purchasing an additional 23,643 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Entrada Therapeutics by 132.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company’s stock valued at $2,215,000 after purchasing an additional 78,953 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in shares of Entrada Therapeutics by 13.4% in the second quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock worth $1,787,000 after purchasing an additional 14,838 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on TRDA shares. Oppenheimer raised their price objective on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, November 6th. HC Wainwright raised their price target on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.